Prot #CA209-816: Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC

Project: Research project

Project Details

StatusFinished
Effective start/end date8/28/17 → 8/28/24

Funding

  • Bristol-Myers Squibb Company ((OE) Prot #CA209-816)